Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box
about
Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and GiardiaOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondIdentification of MMV Malaria Box inhibitors of Perkinsus marinus using an ATP-based bioluminescence assayScreening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar EchinococcosisBiological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathwayCryptosporidium in humans and animals-a one health approach to prophylaxis.A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosisRepurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolyticaRepurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.In Vitro Screening of the Open-Source Medicines for Malaria Venture Malaria Box Reveals Novel Compounds with Profound Activities against Theileria annulata SchizontsExtensive Shared Chemosensitivity between Malaria and Babesiosis Blood-Stage Parasites.Treatment of Cryptosporidium: What We Know, Gaps, and the Way ForwardVirtual Screening and Experimental Validation Identify Novel Inhibitors of the Plasmodium falciparum Atg8-Atg3 Protein-Protein Interaction.A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments.Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways.A novel in vitro image-based assay identifies new drug leads for giardiasis.Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.Susceptibility Testing of Medically Important Parasites.Addressing Cryptosporidium Infection among Young Children in Low-Income Settings: The Crucial Role of New and Existing Drugs for Reducing Morbidity and Mortality.Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii.Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box.A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open Access Malaria Box.Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules.Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry.The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
P2860
Q26774724-5E5F16B8-399D-4E4D-B3A4-AA59A3E88179Q27826351-27C8699D-51DA-4521-B660-BDCCBDEE77C9Q28544008-8C6BEB30-0B1C-4792-9048-257514E07720Q28550703-A5E78906-45F5-4EB5-84F9-683135A9F350Q28821118-2E3721A4-3898-4F09-9156-69A968B54CDDQ30248799-0E0F771D-5B67-47DE-8287-D64B7C63AF04Q30361870-A2A2E9E8-9E88-470C-BCBB-5C2201CA4E1BQ30487158-B3542FE2-8222-40E8-8B02-7F1FC5679CEDQ30487641-C88AEB3D-509E-4D70-A6A4-D35311608F9BQ30489095-21DD30D6-27AC-4AAE-86B0-3B17DAAF78C1Q30788575-B6CDCBF8-8D98-4E70-951E-1B826A16D9EFQ34501816-8434418B-521C-482F-85F1-2259E1D4ACA3Q35889533-5ADA8F92-2F75-4A22-AEDC-F127D45CA38FQ36137064-587E1372-2750-4BDD-A328-BB21D66DC621Q37358648-A7183526-E89D-4C80-81D3-09EAB6E390F3Q37629375-98BDEBC3-1B81-4507-B35E-B85E109C50E6Q38695331-1C6AEFE1-9784-4050-AB84-4DC52755E88AQ38820687-79CC9A45-09A7-4AD5-9AF7-FAD43F95D0F9Q38886453-8B05D2DF-9C99-4174-B91C-51A8956C9D57Q39020376-7ACA187B-21FF-4455-B877-7C1DEC19C659Q43063649-584678F6-ABBD-49C0-BE0B-5816D2F23A43Q47198396-DC9D3AF5-687C-49B4-B50A-54AFEA43ECD3Q47381598-67E2FBB5-23CC-4DB9-94B1-B9DB28A68298Q48016385-C50DED0C-5011-48A5-96B0-102BECD8B91FQ48022259-6F12ECAE-1618-47C1-BF88-D4FCA3F699FCQ48022900-84B3C65D-DE6D-4D58-835D-A13D34BB4A22Q50047043-4E370DA5-5A9D-4AED-89CE-2EAD879F2F07Q57041198-21537210-4AE3-4DB9-9DB2-ADAE75862B4D
P2860
Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Identification of Cryptosporid ...... ng the open access malaria box
@ast
Identification of Cryptosporid ...... ng the open access malaria box
@en
type
label
Identification of Cryptosporid ...... ng the open access malaria box
@ast
Identification of Cryptosporid ...... ng the open access malaria box
@en
prefLabel
Identification of Cryptosporid ...... ng the open access malaria box
@ast
Identification of Cryptosporid ...... ng the open access malaria box
@en
P2093
P2860
P356
P1476
Identification of Cryptosporid ...... ng the open access malaria box
@en
P2093
Christopher D Huston
Jenna E Foderaro
Kovi Bessoff
Rajiv S Jumani
Thomas Spangenberg
P2860
P304
P356
10.1128/AAC.02641-13
P407
P50
P577
2014-02-24T00:00:00Z